Eos, Goddess of Treg Cell Reprogramming  by Rieder, Sadiye Amcaoglu & Shevach, Ethan M.
Immunity
PreviewsEos, Goddess of Treg Cell ReprogrammingSadiye Amcaoglu Rieder1 and Ethan M. Shevach1,*
1Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
*Correspondence: eshevach@niaid.nih.gov
http://dx.doi.org/10.1016/j.immuni.2013.05.001
Under certain conditions, Sharma et al. (2013) show in this issue of Immunity that a subpopulation of Foxp3+
regulatory T cells loses expression of the transcription factor Eos and develops into Foxp3+ T helper cells that
facilitate priming of naive CD8+ T cells.In Greekmythology, Eos is the goddess of
the dawn who wakes up each morning to
open the gates of heaven to allow the sun
to rise. In this issue, Sharma et al. (2013)
demonstrate that loss of Eos (encoded
by lkzf4), a member of the Ikaros gene
transcription factor family, plays a critical
role in mediating the transition of Foxp3+
T regulatory cells (Treg) from suppressor
T cells to helper T cells. These reprog-
rammed Tregs then aid in the priming of
naive CD8+ T cells into potent T effector
(Teff) cells. Although numerous studies
have suggested that Foxp3+ Tregs exhibit
plasticity, the concept of Treg plasticity
remains controversial. Some studies sug-
gest that Treg plasticity is the property of
a minor subpopulation of Tregs that tran-
siently express Foxp3 but are not fully
committed to the Treg lineage (Miyao
et al., 2012). In most studies, Treg plas-
ticity is associated with loss of expression
of Foxp3.
Sharma et al. (2009, 2010) demon-
strated that treatment of mice with
a pharmacologic inhibitor of the immuno-
suppressive enzyme indoleamine 2,3-di-
oxygenase (IDO) enhances tumor
immunity by directly dampening Treg
cell suppressor activity. Inhibition of
IDO in tumor-bearing hosts resulted in
Treg cell instability and proinflammatory
cytokine production by reprogrammed
Treg cells (Sharma et al., 2009). By using
a reductionist cell-transfer approach,
Sharma et al. (2010) demonstrated that
many (50%) Treg cells will rapidly un-
dergo reprogramming after immunization
with an antigen delivered in combination
with incomplete Freund’s adjuvant and
CpG (Toll-like receptor 9 agonist). The
reprogrammed Treg cells not only
expressed the cytokines interleukin-2
(IL-2), tumor necrosis factor-a (TNF-a),
and IL-17, but also CD40 ligand
(CD40L), resulting in licensing of dendriticcells (DCs) to cross-present intact pro-
tein antigens to CD8+ T cells. Reprog-
rammed Treg cells continued to express
Foxp3. In tumor-bearing hosts, vaccine-
induced reprogramming of Treg cells
was suppressed, but pharmacologic inhi-
bition of IDO resulted in reprogramming
and enhancement of the antitumor
response.
In the present report, Sharma et al.
(2013) dissect the molecular basis of
Treg cell reprogramming. The authors
confirm that reprogramming does not
depend on the downregulation of Foxp3
and demonstrate that a close correlation
exists between reprogrammed Treg cells
and loss of expression of Eos, a Treg cell
signature transcription factor. Only a
fraction (up to 50%) of Treg cells lose
Eos, and the authors distinguish the
Eos-labile from the Eos-stable Treg cells
by the differential expression of CD103
and CD38. Reprogramming is absolutely
dependent on IL-6. Reprogramming
in vitro is blocked by anti-MHC class II,
indicating that the polyclonal Treg cells
must also be activated via their TCR. Sur-
prisingly, the Eos-labile and Eos-stable
subsets are generated during the intra-
thymic development of Treg cells, and
the development of the labile subset is
also dependent on IL-6 because the
Eos-labile subset is absent from IL-6
deficient mice. The reprogrammed Treg
cells function in a manner identical to
conventional T helper cells and utilize
CD40L to license the DCs for cross-
presentation (Sharma et al., 2010).
Ultimately, reprogramming is a com-
plex, intricately orchestrated response
involving activated DCs, activated Teff
cells, cognate MHC-II-self-peptide inter-
action between DCs and Treg cells, and
IL-6 (Figure 1).
Both the Eos-labile and Eos-stable sub-
sets are bona fide Treg cells and exhibit aImmunitysubstantially demethylated TSDR region
of the gene encoding Foxp3. Eos-labile
Treg cells are as suppressive as Eos-sta-
ble Treg cells in in vitro proliferation
studies and in vivo in the colitis model. In
the colitis model, the Eos-labile Treg cells
do not reprogram in the gut but are
capable of reprogramming after immuni-
zation in the same host in draining lymph
nodes. Reprogramming of Eos-labile
Treg cells does not occur in tumor-drain-
ing lymph nodes, secondary to the high
amounts of IDO secreted by the activated
DCs in the tumor microenvironment. IDO
and kynurenine pathway metabolites
inhibit the phosphorylation of STAT3 by
binding to the aryl hydrocarbon receptor
(AhR), thereby keeping Eos expression
stable within the Treg cells.
One previous study has described a
critical role of Eos in Treg cell function.
Pan et al. (2009) demonstrated that
Foxp3 and Eos coimmunoprecipiated in
lysates from Treg cells. In this study, the
investigators transduced Foxp3 expres-
sion in conventional T cells, which
resulted in the suppression of IL-2 pro-
duction after activation. However, sup-
pression of IL-2 production could be
reversed by gene targeting of Eos with a
specific small interfering RNA (siRNA).
Transfer of Eos siRNA-modified Treg
cells failed to prevent IBD induced by
CD4+CD25 conventional T cells and
transfer of high numbers of Eos siRNA-
modified Treg cells induced colitis. The
majority of genes that were upregulated
following targeting of Eos were genes
that were downregulated by Foxp3,
whereas none of the genes upregulated
by Foxp3 were altered by knockdown of
Eos. However, the CD40L did not appear
to be one of the genes upregulated
following knockdown of Eos. The results
reported by Pan et al. (2009) are compat-
ible with Sharma et al. (2013) in that loss of38, May 23, 2013 ª2013 Elsevier Inc. 849
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Figure 1. Downregulation of the Transcription Factor Eos Is Required for Treg Cell
Reprogramming into T Helper Cells
Vaccination with ovalbumin in incomplete Freund’s adjuvant in the presence of the TLR9 agonist CpG
results in IL-6 secretion by activated DCs in the draining lymph nodes. Recognition of MHC-II and self-
peptide complexes along with IL-6 signaling results in phosphorylation of STAT-3 and subsequent down-
regulation of Eos. Reprogrammed Eos-labile Treg cells express proinflammatory cytokines (e.g., IL-2 and
IL-17), upregulate CD40L, and license DCs for antigen presentation and CD8+ T cell priming.
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pressor function and acquisition of a
proinflammatory phenotype by the Eos-
deficient Treg cells.
There are certain aspects of the model
system described by Sharma et al.
(2009, 2010, 2013) that need to be
explored in greater depth. They propose
the parallel development of two funda-
mentally separate populations of thymic-
derived Treg cells. One develops in the
absence of IL-6, expresses stable levels
of Eos, and is not subject to Eos loss or re-
programming. The second population re-
quires the presence of IL-6 for intrathymic
development, expresses labile levels of
Eos, and under certain conditions rapidly
develops a T helper cell phenotype. This
model is consistent with the concept
that Foxp3 can interact with many other
transcription factors (e.g., Eos, IRF4,
Satb1, Lef1, and GATA-1). It may be that
each of these interactions controls a
segment of Treg cell signature genes,850 Immunity 38, May 23, 2013 ª2013 Elseviwhich in turn dictate different aspects of
Treg cell function. For example, the Eos-
Foxp3 complex may selectively control
CD40L expression and suppression of
some proinflammatory cytokines. How-
ever, more recent computational models
(Fu et al., 2012) suggest that the combina-
tion of Foxp3 with any of one of its cofac-
tors is sufficient to lock in the entire Treg
cell signature and that the Treg cell signa-
ture can be maintained after inactivation
of any single cofactor. It thus remains
possible that the process of reprogram-
ming involves loss of other cofactors in
addition to Eos.
The Eos-labile population may
comprise 30%–50% of the total pop-
ulation of Foxp3+ Treg cells. It is some-
what surprising that such a major
proportion of Foxp3+ Treg cells would be
so prone to develop into producers of
proinflammatory cytokines and poten-
tially into autoimmune Teff cells. Sharma
et al. (2103) argue that reprogramming iser Inc.an intrinsic characteristic of Treg cells
that is consistent with their function as
‘‘rapid responders’’ both to suppress
inflammation and in some instances
rapidly provide help. What remains un-
known, at present, is the spectrum of
conditions under which Treg cells un-
dergo reprogramming. Furthermore, one
must consider the possibility that reprog-
ramming is reversible and that once Treg
cells provide help transiently, they can
then re-express Eos and be reborn as
suppressor T cells.
Lastly, one must give credit to the
discoverer of Treg cells, the late Dr.
Richard Gershon, one of the true visionary
immunologists, who first proposed (Ger-
shon et al., 1976) the existence of a
unique cell type that could function as
both a helper and a suppressor—the
‘‘hermaphrocyte.’’ The Eos-labile Treg
cell subpopulation described by Sharma
et al. (2013) certainly fits this definition.REFERENCES
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